HIV, TB and ART: the CD4 enigma

TL;DR

This paper reviews the complexities of CD4 T-cell counts in HIV and TB, highlighting their variability and the need for better understanding to improve clinical decision-making and disease management.

Contribution

It synthesizes current knowledge on CD4 count dynamics in HIV and TB, identifying gaps and proposing directions for future research to enhance clinical interpretation.

Findings

CD4 counts vary widely within and among populations.

The decline of CD4 counts during HIV infection is not well understood.

More research is needed to interpret CD4 counts accurately in clinical practice.

Abstract

The concentration of CD4 T-lymphocytes (CD4 count), in a person's plasma is widely used to decide when to start HIV-positive people on anti-retroviral therapy (ART) and to predict the impact of ART on the future course of HIV and tuberculosis (TB). However, CD4 cell-counts vary widely within and among populations and depend on many factors besides HIV-infection. The way in which CD4 counts decline over the course of HIV infection is neither well understood nor widely agreed. We review what is known about CD4 counts in relation to HIV and TB and discuss areas in which more research is needed to build a consensus on how to interpret and use CD4 counts in clinical practice and to develop a better understanding of the dynamics and control of HIV and HIV-related TB.